Key Takeaways
- Canada’s Drug Agency (CDA-AMC) has published a new position statement on the use of artificial intelligence (AI) methods in health technology assessments (HTAs).
Drug companies that are considering using artificial intelligence (AI)-informed evidence in the health technology assessment dossiers they submit in Canada...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?